Skip to main content
Gene Editing Services hero - blue

OpenCRISPR™-1
The Science Behind
AI-Designed Gene Editing

OpenCRISPR-1™ & StemEdit: AI-Designed Genome Editing

Our latest clinical gene editing offerings combine REPROCELL’s StemRNA™ Clinical iPSC Seed Clones with OpenCRISPR-1™, an AI-designed genome editing system licensed from Profluent Bio (Emeryville, CA, USA) to enable streamlined engineering workflows and ensure a GMP-aligned, traceable, and regulatory-ready platform from the outset.

REPROCELL has integrated OC-1 into its StemEdit gene editing platform and developed it as a purified, ready-to-use protein for in-house genome editing research.

Reduced off-target edits for safer clinical gene modification

Feature Value for Clinical Projects
AI-Designed Editor Proprietary design using generative models for optimized precision beyond natural CRISPR systems.
High Specificity Reduced off-target edits for safer clinical gene modification.
Broad Targeting Enables complex edits, including base changes and immune-evasive designs.
Clinical Alignment Built for translational research and cell therapy applications.


Advantages of StemEdit Clinical Gene Editing Over Other Caspases

Broader targeting scope

Improved safety & specificity

Can be used with existing Cas9 guides or with customized “designer” editors

Platform scalability & democratization

Accelerated therapeutic development


How OpenCRISPR-1 Works

AI Meets Gene Editing

OpenCRISPR-1’s design begins with large protein language models (LLMs) pre-trained on millions of naturally occurring CRISPR–Cas sequences to learn the underlying principles of functional genome editors. These models are then fine-tuned specifically on CRISPR–Cas data to guide generation toward proteins with the structural and functional characteristics of Cas9-like nucleases, creating novel gene editors far outside the range of sequences found in nature.

From millions of AI-generated candidates, OpenCRISPR-1 was identified for its strong editing activity, on-target efficiency comparable to traditional SpCas9, and reduced off-target effects in human cells, addressing key challenges in precision editing for clinical use. The system also supports fusion with base-editing domains to enable single-base conversions without double-strand breaks, thereby broadening its applicability for therapeutic workflows (Ruffolo et al., 2025).

Creation_of_OpenCRISPR-1_OC-1

Figure 1. AI-driven design of OpenCRISPR-1. Large language models (LLMs) are first pretrained on a diverse, evolution-wide set of protein sequences - enabling them to learn general constraints of protein evolution and then fine-tuned with CRISPR/Cas (nuclease + nucleic acid) data to generate novel, functional Cas-like proteins such as OpenCRISPR-1.

OpenCRISP-1_OC-1_Protein

Figure 2. Mechanism of CRISPR-guided DNA targeting. In CRISPR-based editing systems like OpenCRISPR-1, a guide RNA directs the editor protein to a specific DNA sequence, where catalytic domains introduce precise edits. OpenCRISPR-1’s AI-designed architecture maintains this core mechanism while enhancing on-target specificity and reducing off-target activity

REPROCELL & Profluent Bio: Licensing Explained

 License included for StemEdit Gene Editing Services and Hypoimmune iPSC lines
Research • Clinical • Commercial

For StemEdit Gene Editing Services and eligible off-the-shelf Hypoimmune iPSC lines, the applicable license for research, clinical, and commercial use is included with the product or service. No separate or additional license for the StemEdit gene editing platform is required, subject to the applicable terms of use and service agreement.

For customers using StemEdit OC-1 Protein in-house, the product is available in Research and GMP formats. Commercial use requires a separate commercial-use agreement with Profluent Bio.

Please note: Users remain responsible for ensuring compliance with applicable third-party intellectual property covering guide RNAs, delivery methods, and downstream applications.


References

  1. Evangelou C. OpenCRISPR-1: Generative AI Meets CRISPR. CRISPR Medicine News (2024).
  2. Ruffolo JA, Nayfach S, Gallagher J, et al. Design of highly functional genome editors by modelling CRISPR-Cas sequences. Nature 645(8080):518-525, (2025).
  3. Thomson T, Li G, Strilchuk A, et al. Harnessing artificial intelligence to advance CRISPR-based genome editing technologies. Nature Reviews Genetics 27, pages 212–230, (2026).

Contact our experts